Literature DB >> 6540399

Control of on/off phenomenon by continuous intravenous infusion of levodopa.

N Quinn, J D Parkes, C D Marsden.   

Abstract

In 10 parkinsonian patients with severe, chaotic clinical response fluctuations, oral levodopa treatment was replaced by continuous intravenous infusion of levodopa (with orally administered benserazide). Four patients were also given levodopa infusions in addition to their usual oral treatment. All patients remained continuously mobile and ambulant during the infusions. Side effects were minimal, except in two patients with diphasic dyskinesias whose abnormal movements were consistently suppressed by a further increase in the rate of levodopa administration, only to return after an interval. If a soluble nonacidic dopamine replacement drug can be developed for continuous subcutaneous infusion, "brittle" parkinsonians may be chronically controlled by portable, minipump technology.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540399     DOI: 10.1212/wnl.34.9.1131

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  44 in total

1.  Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.

Authors:  H D Kao; A Traboulsi; S Itoh; L Dittert; A Hussain
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 2.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

3.  Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.

Authors:  E Bredberg; J Tedroff; S M Aquilonius; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.

Authors:  E C Wolters; H J Tesselaar
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

5.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

6.  Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

Authors:  Amnon C Sintov; Haim V Levy; Igor Greenberg
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

7.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

Review 8.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

9.  Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Authors:  Dag Nyholm; Per Odin; Anders Johansson; Krai Chatamra; Charles Locke; Sandeep Dutta; Ahmed A Othman
Journal:  AAPS J       Date:  2012-12-11       Impact factor: 4.009

Review 10.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.